Drug intelligence / Profile preview

23ND03

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules

Overview

23ND03 is a small molecule drug candidate currently in the discovery phase of development by HK inno.N (formerly CJ Healthcare). It is being investigated for the treatment of hyperlipidemia. As a discovery-stage asset, specific details regarding its molecular target, mechanism of action, and pharmacological profile have not yet been disclosed by the developer. It represents part of HK inno.N's expanding pipeline in metabolic and chronic diseases.

Beyond the preview

Go deeper on 23ND03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 23ND03.

Explore the full profile